MKNK1 and cancer: Although non-specific effects of CGP 57380 is reported, we believe that our additional experiments using the S209D mutant, Mnk1/2 KO MEFs and Mnk1 shRNA knockdown, all support the idea that CGP 57380 acts via the Mnk1/2-eIF4E pathway fairly specifically and may be useful as a tool to sensitize tumour cells to anti-cancer treatments.